LYTIX: Lytix Biopharma presenterer late-breaking fase II-resultater fra NeoLIPA på ESMO IO 2026

Oslo, Norway, November 9, 2026 - Lytix Biopharma ASA ("Lytix"), a clinical-stage
oncology company developing novel intratumoral cancer therapies, today announced
that its late-breaking abstract presenting updated results from the Phase II
NeoLIPA trial has been accepted for oral presentation in a Proffered Paper
session at the ESMO Immuno-Oncology & Advanced Therapies Congress 2026. The
congress will take place December 14-16, 2026, in London, United Kingdom.

Late-breaking abstracts present new data that were not yet available at the
regular abstract submission deadline. The congress Scientific Committee selects
abstracts for presentation, and ESMO defines its Proffered Paper format as an
"oral presentation of original data of superior quality". Proffered Paper
presentations are also discussed by experts invited by ESMO. 

On November 3, 2026, Lytix announced that NeoLIPA met its primary endpoint. The
results will be presented by Henrik Jespersen, MD, Principal Investigator of the
NeoLIPA trial at Oslo University Hospital, The Norwegian Radium Hospital.
NeoLIPA is an investigator-initiated Phase II study led by Oslo University
Hospital in patients with resectable melanoma, the most serious form of skin
cancer.  The study evaluates ruxotemitide in combination with pembrolizumab
before surgery. In line with ESMO's embargo policy, the data will be made public
on the day of presentation.

"We are very pleased that the NeoLIPA abstract has been selected for a Proffered
Paper presentation at ESMO IO, and we congratulate Dr. Jespersen and the team at
the Norwegian Radium Hospital. We look forward to sharing the results with the
scientific and clinical community in December," said Øystein Rekdal, CEO of
Lytix Biopharma.

"Being selected for a Proffered Paper presentation is a great opportunity to
share the NeoLIPA results with the international oncology community. I look
forward to presenting the updated data in London and discussing them with
colleagues working to improve outcomes for patients with melanoma," said Henrik
Jespersen, MD, Principal Investigator of the NeoLIPA trial.

Presentation details
 Title: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable
Melanoma: Updated Results From The Phase II NeoLIPA Trial
Abstract: LBA2
Presenter: Henrik Jespersen, MD, Oslo University Hospital, The Norwegian Radium
Hospital
Date & Time: December 15, 2026, 11:40 - 11:50

About NeoLIPA 
NeoLIPA is an investigator-initiated, single-arm, open-label Phase II study led
by Oslo University Hospital. It evaluates ruxotemitide, administered directly
into tumors, in combination with pembrolizumab before surgery in patients with
resectable melanoma (ClinicalTrials.gov: NCT06651151, EU CT 2023-508649-42-00).
The primary endpoint is pCR. The protocol prespecified a threshold of at least
40% pCR, with the lower bound of the 95% confidence interval above the
historical pCR of 20% for pembrolizumab alone. 

For more information about NeoLIPA and the treatment approach, visit
https://www.lytixbiopharma.com/clinical-trials. 

About melanoma
Melanoma is the most serious form of skin cancer. In the United States, an
estimated 112,000 new cases of invasive melanoma will be diagnosed in 2026, and
approximately 8,510 people are expected to die from the disease. Incidence has
increased in most Western countries in recent decades, and there is continued
interest in effective treatment options before surgery.

About ruxotemitide 
Ruxotemitide (LTX-315) is an investigational, first-in-class oncolytic peptide
designed for intratumoral administration. The molecule disrupts tumor cells
locally, leading to the release of tumor antigens and danger signals that
activate systemic antitumor immune responses, with the aim of preventing cancer
recurrence. Its mode of action provides a rationale for combination with immune
checkpoint inhibitors such as pembrolizumab.

About Lytix Biopharma ASA
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotech company
with a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to achieve durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules with potential across multiple cancer
indications and treatment settings, both as monotherapy and in combination
therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker
symbol LYTIX.

For further information, please contact:
Øystein Rekdal, CEO
E-mail: oystein.rekdal@lytixbiopharma.com 
Ph +47 975 73 358

Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com 
Ph +47 952 60 512

For more information, visit www.lytixbiopharma.com.
Gjest Breistein\, CFO\
E-mail: gjest.breistein@lytixbiopharma.com \
Ph +47 952 60 512\
\
For more information\, visit www.lytixbiopharma.com.\